Drug company Mylan has finalized a $30 million settlement with the Securities and Exchange Commission for alleged accounting and disclosure failures surrounding its popular EpiPen.

Drug company Mylan has finalized a $30 million settlement with the Securities and Exchange Commission for alleged accounting and disclosure failures surrounding its popular EpiPen.